Elanco at UBS Global Healthcare Conference: growth, margins and leverage

Elanco Animal Health presented a strong outlook at the UBS Global Healthcare Conference, highlighting growth, improved margins, and reduced leverage. The company reported a 9% rise in organic revenue and an 11% growth, attributed to the pet business, which showed 13% growth in U.S. Pet Health and 17% in international pet health.

Net leverage dropped to 2.9 times, ahead of the company's 2027 target of 3.0 times. New products Zenrelia, Credelio Quattro, and Befrena were highlighted as key growth drivers, with Credelio Quattro present in 55% of veterinary clinics and Zenrelia in 67%. Pricing strength was noted as a positive factor, but management expects it to return to its historical range.

The company also emphasized its efforts in expanding clinic adoption and converting puppies to Elanco products, indicating future growth potential.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.